177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

By afschroeder • November 13, 2025

Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Nov 12:JCO2501553. doi: 10.1200/JCO-25-01553. Epub ahead of print. PMID: 41223345.

Tags: Cardiology/Epi, DOM STAT, General Internal Medicine, Hematology/Oncology, Publications, Veterans Administration

Utilizing stored implanted cardiac defibrillator electrograms to target localized fascicular denetworking in catheter ablation of ventricular fibrillation

Kerley RN, Huang H, Batnyam U, Nazer B, Sharma E, Bradfield JS, Hayase JH, Romero J, Vo C, Dhakal BP, Winterfield J, Tedrow UB, Sauer[...]

Post Market Data-Real World Safety Evaluation of Pulsed Field Ablation – and Beyond

Dhruva SS, Kadakia KT, Shivkumar K. Post Market Data-Real World Safety Evaluation of Pulsed Field Ablation - and Beyond. J Am Coll Cardiol. 2025 Nov[...]

Explaining subgroup findings using spline regression: Risk of kidney failure in patients with heart failure and normal kidney function receiving RAS inhibitors

Patel SS, Heidenreich PA, Morgan CJ, Faselis C, Zhang S, Wu WC, Lam PH, Palant CE, Zeng-Treitler Q, Fonarow GC, Ahmed A. Explaining subgroup findings[...]